Share：
Share this content in WeChat
X
[Chinese] [PDF] 67 1
• Review •
Advances in MRI omics and multi-omics in the study of breast cancer tumor microenvironment
WANG Hao  CHEN Mingming  HAN Yaoqi  OUYANG Aimei 

DOI:10.12015/issn.1674-8034.2026.07.023.


[Abstract] The breast cancer tumor microenvironment is composed of immune cells, fibroblasts, extracellular matrix, vasculature, and other components, and plays a critical role in tumor initiation and progression, therapeutic response, and prognosis. Although conventional pathology and single-molecule assays can provide localized information, they are limited in their ability to noninvasively, dynamically, and comprehensively characterize the heterogeneity of the tumor microenvironment. In recent years, magnetic resonance imaging radiomics, based on multiparametric imaging and high-throughput feature extraction, has made substantial progress in characterizing the breast cancer microenvironment. Meanwhile, advances in genomics, transcriptomics, proteomics, and metabolomics have provided important support for elucidating the associations between imaging phenotypes and underlying molecular mechanisms. However, current studies still face several challenges, including small sample sizes, insufficient standardization, limited model generalizability, and difficulties in multi-omics integration, and comprehensive systematic reviews in this area remain scarce. This review focuses on the key components and biological processes of the breast cancer tumor microenvironment, summarizes the applications of magnetic resonance imaging radiomics in assessing the immune microenvironment, stromal remodeling, angiogenesis, and treatment response, and further reviews the current status of integrative analyses combining radiomics with genomics, transcriptomics, proteomics, and pathomics. The aim is to synthesize the major findings and challenges in this field, clarify the potential value of multi-omics synergy for precise evaluation of the breast cancer tumor microenvironment, and provide references for future research and clinical translation.
[Keywords] magnetic resonance imaging；radiomics；multi-omics；breast cancer；tumor microenvironment

WANG Hao1, 2   CHEN Mingming2, 3   HAN Yaoqi2   OUYANG Aimei2*  

1 Graduate Faculty, Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan 250117, China

2 Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China

3 School of Medical Imaging, Shandong Second Medical University, Weifang 261053, China

Corresponding author: OUYANG A M, E-mail: 13370582510@163.com

Conflicts of interest   None.

Received  2026-02-25
Accepted  2026-05-05
DOI: 10.12015/issn.1674-8034.2026.07.023
DOI:10.12015/issn.1674-8034.2026.07.023.

[1]
SIEGEL R L, KRATZER T B, GIAQUINTO A N, et al. Cancer statistics, 2025[J]. CA Cancer J Clin, 2025, 75(1): 10-45. DOI: 10.3322/caac.21871.
[2]
KIM E S, HAM S, SEO B K, et al. Optimized prediction of breast cancer tumor microenvironment using MRI-based intratumoral and peritumoral radiomics: a prospective study[J/OL]. Front Oncol, 2025, 15: 1654508 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41278298/. DOI: 10.3389/fonc.2025.1654508.
[3]
WANG W, HUANG W C, YANG X Q, et al. Multimodal radiopathomics approach for predictions of prognosis and immunotherapy response in patients with gastric cancer: a multicohort retrospective study[J]. Int J Surg, 2025, 111(11): 7606-7621. DOI: 10.1097/js9.0000000000002939.
[4]
LAMBIN P, LEIJENAAR R T H, DEIST T M, et al. Radiomics: the bridge between medical imaging and personalized medicine[J]. Nat Rev Clin Oncol, 2017, 14(12): 749-762. DOI: 10.1038/nrclinonc.2017.141.
[5]
JIANG Y M, ZHOU K N, SUN Z P, et al. Non-invasive tumor microenvironment evaluation and treatment response prediction in gastric cancer using deep learning radiomics[J/OL]. Cell Rep Med, 2023, 4(8): 101146 [2026-02-24]. https://linkinghub.elsevier.com/retrieve/pii/S2666379123002999. DOI: 10.1016/j.xcrm.2023.101146.
[6]
LANEY V E A, ZHAO W, HWANG I M, et al. MR molecular imaging for monitoring and predicting tumor responses to immunotherapy[J]. Theranostics, 2025, 15(18): 10045-10063. DOI: 10.7150/thno.106481.
[7]
SHI Z W, HUANG X M, CHENG Z L, et al. MRI-based quantification of intratumoral heterogeneity for predicting treatment response to neoadjuvant chemotherapy in breast cancer[J/OL]. Radiology, 2023, 308: e222830[2026-02-24]. https://pubs.rsna.org/doi/10.1148/radiol.222830. DOI: 10.1148/radiol.222830.
[8]
WU Z Q, OUYANG S Y, GAO J D, et al. Role of radiomics-based multiomics panel in the microenvironment and prognosis of hepatocellular carcinoma[J]. Acad Radiol, 2025, 32(4): 1961-1970. DOI: 10.1016/j.acra.2024.12.039.
[9]
GAO J H, YE F D, HAN F, et al. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma[J/OL]. Front Immunol, 2022, 13: 956679 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/36177018/. DOI: 10.3389/fimmu.2022.956679.
[10]
LI Y Z, LIANG Y, ZHAO W H, et al. Research progress on MRI radiomics in predicting the efficacy of neoadjuvant chemotherapy for breast cancer[J/OL]. Chin J Magn Reson Imaging, [2026-04-27]. https://link.cnki.net/urlid/11.5902.R.20260427.0924.002.
[11]
LIN M X, JIANG Y M, CHEN Y F, et al. Multidimensional regulatory mechanisms of extracellular matrix stiffness in breast cancer and its prospects for clinical translation[J]. Clin Breast Cancer, 2026, 26(4): 85-97. DOI: 10.1016/j.clbc.2026.02.017.
[12]
KUNDU M, BUTTI R, PANDA V K, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer[J/OL]. Mol Cancer, 2024, 23(1): 92 [2026-02-24]. https://link.springer.com/article/10.1186/s12943-024-01990-4. DOI: 10.1186/s12943-024-01990-4.
[13]
FANG C Y, ZHANG J T, LI J Z, et al. Clinical-radiomics nomogram for identifying HER2 status in patients with breast cancer: a multicenter study[J/OL]. Front Oncol, 2022, 12: 922185 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/36158700/. DOI: 10.3389/fonc.2022.922185.
[14]
MA W H, YANG L, ZHANG Y, et al. Heterogeneity assessment of breast cancer tumor microenvironment: multiparametric quantitative analysis with DCE-MRI and discovery of radiomics biomarkers[J/OL]. Breast Cancer (Dove Med Press), 2025, 17: 573-581 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40657027/. DOI: 10.2147/BCTT.S530834.
[15]
ZHANG X L, CHEN X Y, FU Y, et al. Study on heterogeneity of vascularity and cellularity via multiparametric MRI habitat imaging in breast cancer[J/OL]. BMC Med Imaging, 2025, 25(1): 159 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40361010/. DOI: 10.1186/s12880-025-01698-x.
[16]
YUAN Q, HONG Z P, YE R J, et al. Integrating deep feature extraction and MRI radiomics for survival prediction in breast cancer after neoadjuvant chemotherapy[J]. Acad Radiol, 2026, 33(3): 872-888. DOI: 10.1016/j.acra.2025.10.050.
[17]
WU J, LI Y X, GONG W Q, et al. Multi-modality radiomics diagnosis of breast cancer based on MRI, ultrasound and mammography[J/OL]. BMC Med Imaging, 2025, 25(1): 265 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40615781/. DOI: 10.1186/s12880-025-01767-1.
[18]
CHEN S, HUANG G Z, YAO Z H, et al. Prognostic value of PD-L1 expression on tumor-infiltrating immune cells and neutrophil-to-lymphocyte ratio in patients with biliary tract cancer[J/OL]. Front Immunol, 2025, 16: 1729542 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41737495/. DOI: 10.3389/fimmu.2025.1729542.
[19]
MA J F, CHEN K, LI S R, et al. MRI-based radiomic models to predict surgical margin status and infer tumor immune microenvironment in breast cancer patients with breast-conserving surgery: a multicenter validation study[J]. Eur Radiol, 2024, 34(3): 1774-1789. DOI: 10.1007/s00330-023-10144-x.
[20]
GAO Y, LI B, JIN Y Z, et al. Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis[J]. Oncogene, 2025, 44(27): 2268-2282. DOI: 10.1038/s41388-025-03388-y.
[21]
KUANG J, HUANG S T, HUANG X H, et al. Interpretable machine learning model for predicting preoperative histological grade of invasive breast cancer based on high resolution delay period of magnetic resonance imaging[J]. Chin J Magn Reson Imaging, 2025, 16(5): 164-169, 216. DOI: 10.12015/issn.1674-8034.2025.05.025.
[22]
PENG Y, HU X G, LIU Y L, et al. The feasibility of the radiomics models for tumor-infiltrating lymphocytes level prediction in breast cancer based on dynamic contrast-enhanced MRI[J/OL]. BMC Med Imaging, 2025, 25(1): 420 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41120945/. DOI: 10.1186/s12880-025-01968-8.
[23]
LIU X Y, FENG Y, ZHANG X F. Interpretable machine learning model based on MRI habitat imaging to predict tumor infiltrating lymphocyte levels in breast cancer[J]. J Clin Radiol, 2025, 44(9): 1608-1614. DOI: 10.13437/j.cnki.jcr.2025.09.013.
[24]
QIAN H, REN X J, XU M S, et al. Magnetic resonance imaging-based radiomics was used to evaluate the level of prognosis-related immune cell infiltration in breast cancer tumor microenvironment[J/OL]. BMC Med Imaging, 2024, 24(1): 31 [2026-02-24]. https://link.springer.com/article/10.1186/s12880-024-01212-9. DOI: 10.1186/s12880-024-01212-9.
[25]
LAWLER J. Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1[J/OL]. Semin Cancer Biol, 2022, 86: 126-135 [2026-02-24]. https://www.sciencedirect.com/science/article/pii/S1044579X22002036via%3Dihub. DOI: 10.1016/j.semcancer.2022.09.006.
[26]
LI F R, JIN C N, PAN Y C, et al. Construction of a stromal cell-related prognostic signature based on a 101-combination machine learning framework for predicting prognosis and immunotherapy response in triple-negative breast cancer[J/OL]. Front Immunol, 2025, 16: 1544348 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40438115/. DOI: 10.3389/fimmu.2025.1544348.
[27]
XIE T W, GONG J, ZHAO Q F, et al. Development and validation of peritumoral vascular and intratumoral radiomics to predict pathologic complete responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer[J/OL]. BMC Med Imaging, 2024, 24(1): 136 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/38844842/. DOI: 10.1186/s12880-024-01311-7.
[28]
CASTALDO R, GARBINO N, CAVALIERE C, et al. A complex radiomic signature in luminal breast cancer from a weighted statistical framework: a pilot study[J/OL]. Diagnostics (Basel), 2022, 12(2): 499 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/35204589/. DOI: 10.3390/diagnostics12020499.
[29]
WU Y Y, SHI Y Y, LUO Z Y, et al. Spatial multi-omics analysis of tumor-stroma boundary cell features for predicting breast cancer progression and therapy response[J/OL]. Front Cell Dev Biol, 2025, 13: 1570696 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40206396/. DOI: 10.3389/fcell.2025.1570696.
[30]
WU L X, LIU C, HU W C. Comprehensive investigation of matrix metalloproteinases in skin cutaneous melanoma: diagnostic, prognostic, and therapeutic insights[J/OL]. Sci Rep, 2025, 15(1): 2152 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/39820824/. DOI: 10.1038/s41598-025-85887-2.
[31]
RØMER A M A, THORSETH M L, MADSEN D H. Immune modulatory properties of collagen in cancer[J/OL]. Front Immunol, 2021, 12: 791453 [2026-02-24]. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.791453/full. DOI: 10.3389/fimmu.2021.791453.
[32]
FLAHERTY R L, HUGHES F, SFLOMOS G, et al. LOX inhibition disrupts a collagen-integrin-MYC axis to suppress progression of invasive lobular carcinoma[J/OL]. Cancer Res, 2026 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41706704/. DOI: 10.1158/0008-5472.CAN-25-3490.
[33]
LAVIE D, BEN-SHMUEL A, EREZ N, et al. Cancer-associated fibroblasts in the single-cell era[J]. Nat Cancer, 2022, 3(7): 793-807. DOI: 10.1038/s43018-022-00411-z.
[34]
DO K V, TRAN A V, PHAM A D, et al. Molecular remodeling of cancer-associated fibroblasts in breast cancer patients receiving anti-PD-1 immunotherapy[J/OL]. Front Oncol, 2026, 16: 1754311 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41815540/. DOI: 10.3389/fonc.2026.1754311.
[35]
JIANG N, ZHANG Y, LI G F, et al. Integration of dual-energy CT parameters and radiomics features for non-invasive prediction of α-SMA and CD8 + T cell in non-small cell lung cancer[J/OL]. Front Med, 2026, 13: 1792692 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41889495/. DOI: 10.3389/fmed.2026.1792692.
[36]
CHANG S, CHEN Q, GUAN G N, et al. In situ remodeling of tumor microenvironment via specific cancer-associated fibroblasts subtype engineering to boost antitumor immunity[J]. ACS Nano, 2025, 19(43): 37815-37836.
[37]
YU Z H, XU H L, WANG S, et al. Integrating spatial and single-cell transcriptomes reveals the role of COL1A2(+)MMP1(+/-) cancer-associated fibroblasts in ER-positive breast cancer[J/OL]. Cancer Cell Int, 2025, 25(1): 82 [2026-02-24]. https://link.springer.com/article/10.1186/s12935-025-03705-1. DOI: 10.1186/s12935-025-03705-1.
[38]
WAN X Y, GUAN S D, HOU Y X, et al. FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts[J]. Theranostics, 2021, 11(10): 4975-4991. DOI: 10.7150/thno.55074.
[39]
XU M Z, WANG A L, SHAN D Q, et al. Multimodal radiomics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer: integration of amide proton transfer weighted imaging in radiomics[J/OL]. BMC Med Imaging, 2026 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41947063/. DOI: 10.1186/s12880-026-02311-5.
[40]
FAN M, WANG K L, ZHANG Y, et al. Radiogenomic analysis of cellular tumor-stroma heterogeneity as a prognostic predictor in breast cancer[J/OL]. J Transl Med, 2023, 21(1): 851 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/38007511/. DOI: 10.1186/s12967-023-04748-6.
[41]
TENG X Z, ZHANG J, LAI Q P, et al. Tumor heterogeneity index from DCE-MRI for AKT-inhibition responder identification and reveals hot immune microenvironment for patients with breast cancer: a multi-omics analysis of I-SPY2 trial[J/OL]. Breast Cancer Res, 2026, 28(1): 39 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41645311/. DOI: 10.1186/s13058-026-02219-6.
[42]
JIANG W Y, WU R X, YANG T, et al. Profiling regulatory T lymphocytes within the tumor microenvironment of breast cancer via radiomics[J]. Cancer Med, 2023, 12(24): 21861-21872. DOI: 10.1002/cam4.6757.
[43]
HAN X R, GONG Z Z, GUO Y, et al. Exploration of a noninvasive radiomics classifier for breast cancer tumor microenvironment categorization and prognostic outcome prediction[J/OL]. Eur J Radiol, 2024, 175: 111441 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/38537607/. DOI: 10.1016/j.ejrad.2024.111441.
[44]
WANG G X, WANG S, SONG W B, et al. Integrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer[J/OL]. BMC Cancer, 2025, 25(1): 623 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40197136/. DOI: 10.1186/s12885-025-14029-8.
[45]
SU G H, XIAO Y, JIANG L, et al. Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer[J/OL]. J Transl Med, 2022, 20(1): 471 [2026-02-24]. https://link.springer.com/article/10.1186/s12967-022-03688-x. DOI: 10.1186/s12967-022-03688-x.
[46]
HUANG Y H, SHI Z Y, ZHU T, et al. Longitudinal MRI-driven multi-modality approach for predicting pathological complete response and B cell infiltration in breast cancer[J/OL]. Adv Sci (Weinh), 2025, 12(12): e2413702[2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/39921294/. DOI: 10.1002/advs.202413702.
[47]
DUAN J X, ZHAO Y S, SUN Q C, et al. Imaging-proteomic analysis for prediction of neoadjuvant chemotherapy responses in patients with breast cancer[J]. Cancer Med, 2023, 12(23): 21256-21269. DOI: 10.1002/cam4.6704.
[48]
HACKING S M, WINDSOR G, COOPER R, et al. A novel approach correlating pathologic complete response with digital pathology and radiomics in triple-negative breast cancer[J]. Breast Cancer, 2024, 31(3): 529-535. DOI: 10.1007/s12282-024-01544-y.
[49]
WANG C D, LENG B, YOU R, et al. A transcriptomic biomarker for predicting the response to TACE correlates with the tumor microenvironment and radiomics features in hepatocellular carcinoma[J/OL]. J Hepatocell Carcinoma, 2024, 11: 2321-2337 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/39619603/. DOI: 10.2147/JHC.S480540.
[50]
WU H Y, CAO S Y, XU Z G, et al. Construction of a radiogenomic signature based on endoplasmic reticulum stress for predicting prognosis and systemic combination therapy response in hepatocellular carcinoma[J/OL]. BMC Cancer, 2025, 25(1): 131 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/39849389/. DOI: 10.1186/s12885-025-13433-4.
[51]
PAN D, ZHANG C Y, WANG Y F, et al. Machine learning-based integration of DCE-MRI radiomics for STAT3 expression prediction and survival stratification in breast cancer[J/OL]. Front Immunol, 2025, 16: 1619186 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40636126/. DOI: 10.3389/fimmu.2025.1619186.
[52]
CHEN Y L, HUANG Y H, LI W, et al. Intratumoral microbiota-aided fusion radiomics model for predicting tumor response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer[J/OL]. J Transl Med, 2025, 23(1): 352 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40114207/. DOI: 10.1186/s12967-025-06369-7.
[53]
ZHANG T F, ZHAO L, CUI T T, et al. Spatial-temporal radiogenomics in predicting neoadjuvant chemotherapy efficacy for breast cancer: a comprehensive review[J/OL]. J Transl Med, 2025, 23(1): 681 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40533825/. DOI: 10.1186/s12967-025-06641-w.
[54]
WANG Y F, MA L F, YUAN S J, et al. Multiomics analysis for predicting pathological complete response in triple-negative breast cancer and reflecting tumor heterogeneity[J]. Clin Breast Cancer, 2026, 26(1): 368-380. DOI: 10.1016/j.clbc.2025.08.014.
[55]
JIANG Y Z, MA D, JIN X, et al. Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities[J]. Nat Cancer, 2024, 5(4): 673-690. DOI: 10.1038/s43018-024-00725-0.
[56]
LI Y X, CAO J M, HAI L Y, et al. Multi-scale data reveal a CD24+ MUCL1(+) tumor subgroup associated with unfavorable prognosis in ER+ breast cancer[J/OL]. Front Immunol, 2025, 16: 1695689 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41142825/. DOI: 10.3389/fimmu.2025.1695689.
[57]
YE Z, YUAN J Q, HONG D Q, et al. Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer[J/OL]. Front Immunol, 2025, 16: 1559200 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40170854/. DOI: 10.3389/fimmu.2025.1559200.
[58]
HONG M P, CHEN X B, HUANG X W, et al. A macro-micro-macro radiogenomic framework identifies FIBCD1 as a key immune-modulating biomarker in breast cancer[J/OL]. J Transl Med, 2025, 23(1): 1350 [2026-02-24]. https://link.springer.com/article/10.1186/s12967-025-07389-z. DOI: 10.1186/s12967-025-07389-z.
[59]
SU G H, XIAO Y, YOU C, et al. Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets[J/OL]. Sci Adv, 2023, 9(40): eadf0837 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/37801493/. DOI: 10.1126/sciadv.adf0837.
[60]
HAN X R, GUO Y, YE H F, et al. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response[J/OL]. Breast Cancer Res, 2024, 26(1): 18 [2026-02-24]. https://link.springer.com/article/10.1186/s13058-024-01776-y. DOI: 10.1186/s13058-024-01776-y.
[61]
ZHANG Y W, ZHANG X, ZHONG X, et al. Immunophenotype-guided interpretable radiomics model for predicting neoadjuvant anti-PD-1 response in stage III-IV d-MMR/MSI-H colorectal cancer[J/OL]. J Immunother Cancer, 2025, 13(8): e011569[2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/40759438/. DOI: 10.1136/jitc-2025-011569.
[62]
XU N, GUO X B, OUYANG Z Q, et al. Multiparametric MRI-based radiomics combined with pathomics features for prediction of the efficacy of neoadjuvant chemotherapy in breast cancer[J/OL]. Heliyon, 2024, 10(2): e24371[2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/38298695/. DOI: 10.1016/j.heliyon.2024.e24371.
[63]
CAI D Q, ZHU C, HUANG H X, et al. Lymph node metastasis-associated spatiotemporal mapping of the TFF3-linked niche in breast cancer: integrating radiogenomic signatures with immune-ecosystem remodeling[J/OL]. Research (Wash D C), 2026, 9: 1016 [2026-02-24]. https://pubmed.ncbi.nlm.nih.gov/41551914/. DOI: 10.34133/research.1016.

PREV Research progress of imaging studies of the patients with coronary microvascular disease
NEXT The application progress of radiomics in intrahepatic cholangiocarcinoma
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn